Contribution to Development of Remedies for COVID-19: Focusing on Eritoran

Eritoran (E5564) is Eisai's in-house discovered and developed investigational TLR4 (Toll-Like Receptor 4) antagonist created with natural product organic synthesis technology. It a structural analogue of Lipid A, which an activator endotoxins bacteria. has been previously observed to be safe in 14 clinical studies including large Phase 3 randomized trial severe sepsis. We are participating the international network REMAP-CAP-COVID (Randomized, Embedded, Multi-factorial, Adaptive Platform-Community Acquired Pneumonia COVID) aims for novel coronavirus medicine development through drug repurposing, began collaborative October 2020 designated confirmed patients who hospitalized progressing disease state. hoped that suppressing most upstream activity controls production multiple cytokines, cytokine storm can suppressed pneumonia thus prevented from becoming severe.